Formulating longevity supplements is governed less by efficacy messaging than by physical and chemical stability, because the category’s leading actives are chemically fragile. Three ingredients dominate current formulator pipelines: nicotinamide mononucleotide (NMN), a precursor to nicotinamide adenine dinucleotide (NAD+); urolithin A, a mitophagy activator; and spermidine, an autophagy inducer delivered as a standardized plant extract. Each carries a distinct formulation problem. NMN is strongly hygroscopic and hydrolyzes to nicotinamide. Urolithin A is poorly water soluble and bioavailability limited. Spermidine is dosed in milligram amounts inside a moisture-sensitive wheat-germ extract. Studied doses are roughly 250 to 900 mg/day for NMN, 500 to 1000 mg/day for urolithin A, and 1 to 6 mg/day of spermidine. Regulatory status differs sharply by ingredient and region, and the human evidence is early and best framed as structure/function. This article gives a formulation profile for each hero ingredient, a cross-cutting stability strategy, the regulatory map, quality and analytical requirements, and the trends reshaping the category.
Table of Contents
- What Counts as a Longevity Ingredient
- NMN: Formulating a Hygroscopic NAD+ Precursor
- Urolithin A: Solving Solubility and Bioavailability
- Spermidine: Dosing a Standardized Plant Extract
- Cross-Cutting Formulation and Stability Strategy
- Regulatory Status: A Moving Target
- Quality, Standardization, and the Label-Claim Problem
- Emerging Trends in Longevity Formulation
- Frequently Asked Questions
- Key Takeaways
- Sources
What Counts as a Longevity Ingredient
Longevity ingredients are dietary actives selected to target mechanisms of cellular aging rather than a single nutrient deficiency. The most-studied mechanisms in this category are NAD+ repletion, mitophagy (selective recycling of damaged mitochondria), and autophagy (clearance of damaged cellular components). Unlike established nutrients, these actives are typically high-dose isolates or standardized extracts with demanding physicochemical profiles, which is why formulation and stability, not flavor or compression alone, decide product viability. The category also includes peer ingredients such as resveratrol, fisetin, coenzyme Q10, calcium alpha-ketoglutarate, and collagen peptides, each with its own delivery constraints. For B2B product developers, the practical question is not whether an ingredient is fashionable but whether it can be manufactured, stabilized, and assayed to a reliable specification.
See and download our infographic on longevity ingredient formulation:
NMN: Formulating a Hygroscopic NAD+ Precursor
NMN (beta-nicotinamide mononucleotide, CAS 1094-61-7, molecular weight 334.22 g/mol) is an immediate precursor to NAD+, the cofactor for sirtuins, poly(ADP-ribose) polymerases (PARPs), and cellular redox metabolism. Oral NMN reliably raises blood NAD+ in human trials, but downstream clinical effects are inconsistent. A randomized controlled trial (RCT) in prediabetic postmenopausal women reported a 25% improvement in muscle insulin sensitivity at 250 mg/day over 10 weeks, with no effect on other tissues [1]. A dose-ranging RCT found blood NAD+ rose dose-dependently and framed 600 mg as the practical optimum, with no added benefit at 900 mg [2]. A 2024 meta-analysis of eight RCTs (342 participants), however, found no significant pooled effect on glucose, insulin, or lipids, so benefits should be described cautiously [3]. NMN is generally well tolerated across 250 to 900 mg/day, and it is closely related to nicotinamide riboside, the dephosphorylated precursor that feeds the same NAD+ pool.
Stabilizing NMN Against Moisture and Hydrolysis
NMN is very hygroscopic and degrades chiefly by hydrolysis to nicotinamide, which is both a potency loss and the natural stability-indicating marker, since excess nicotinamide can inhibit sirtuins. In solution, degradation follows apparent first-order kinetics driven mainly by temperature and pH, and is fastest under strong acid or base [18]. In the solid state, amorphous NMN can take up water reversibly until it deliquesces, whereas a defined anhydrous crystalline form is the more robust handling material. The practical controls are to specify a defined crystalline form, hold low water activity throughout manufacturing, and protect finished goods with desiccants and foil or induction-sealed packaging. Aqueous and high-heat processing should be minimized, which makes liposomal, enteric-coated, and especially gummy formats higher-risk for NMN, while a desiccated hard capsule with low-moisture, pH-neutral excipients such as microcrystalline cellulose remains the lowest-stress option. Reducing-sugar excipients are best avoided.
Urolithin A: Solving Solubility and Bioavailability
Urolithin A (CAS 1143-70-0, molecular weight 228.20 g/mol) is a gut-microbiome metabolite of dietary ellagitannins from pomegranate, walnuts, and berries, and it has been studied as a mitophagy activator. Only around 40% of adults, with wide variation across populations, convert dietary precursors into meaningful urolithin A, and this metabotype variability is the documented rationale for supplementing the molecule directly rather than relying on diet [4]. Human RCTs have used a synthetic form. A first-in-human trial established safety and a molecular signature of improved mitochondrial gene expression [4], a four-month RCT in overweight middle-aged adults reported roughly a 12% improvement in muscle strength and lower inflammatory biomarkers [5], and a four-month RCT in adults aged 65 to 90 improved muscle endurance at 1000 mg/day, though the six-minute walk endpoint was not significant [6]. The trials are small, short, and largely sponsored, so claims should remain structure/function and hedged.
Bioavailability Enhancement for a Lipophilic Molecule
Urolithin A is practically insoluble in water, and its low aqueous solubility combined with extensive phase II conjugation is the central bioavailability constraint. The best-documented formulation lever is particle-size reduction: micronized material with a D90 (the size below which 90% of particles fall) under 50 micrometers consistently outperforms coarse material, and finer grades raise peak blood levels further. The clinically validated material is a specific particle-size-engineered dispersible form, not generic powder, which matters when sourcing. The 500 to 1000 mg dose is large, so format selection is a trade-off between mass and absorption. Dispersible stick-pack powders accommodate the dose and were used in the pivotal trials, lipid-fill softgels suit the lipophilic molecule but add pill burden, and gummies or tablets are limited by mass and dissolution. The crystalline solid is otherwise stable, but aqueous solutions are not suitable for storage.
Spermidine: Dosing a Standardized Plant Extract
Spermidine (CAS 124-20-9, molecular weight 145.25 g/mol) is a natural polyamine studied as a caloric-restriction mimetic that induces autophagy, primarily by inhibiting the acetyltransferase EP300 and through hypusination of the translation factor eIF5A. Most mechanistic support is preclinical: in animals, oral spermidine extended lifespan and was cardioprotective in an autophagy-dependent manner [11]. Human evidence is mixed and should be presented candidly. The adequately powered SmartAge RCT (100 older adults, 12 months) was null on its primary cognitive endpoint [9]. A smaller trial in nursing-home elderly reported cognitive improvement but lacked a true placebo, and a large prospective cohort associated higher dietary spermidine intake with lower all-cause mortality, an association that cannot establish causation [10]. No human RCT has yet demonstrated autophagy induction or a hard longevity outcome.
Standardization and Excipient Compatibility
Commercial spermidine is delivered as a standardized wheat-germ extract rather than a pure synthetic, because free-base spermidine is a hygroscopic, alkaline, corrosive low-melting solid that is liquid near room temperature and because the natural-extract pathway has an established regulatory authorization. The formulator consequence is that the product is dosed by declared spermidine content, commonly 1 to 6 mg, inside several hundred milligrams of extract, so the standardization assay and content uniformity govern label accuracy more than for high-dose actives. Spermidine is a nucleophilic polyamine, so reducing sugars and aldehyde-bearing materials should be avoided to prevent Maillard and Schiff-base reactions, and low-water-activity carriers with desiccants are preferred. Microcrystalline cellulose is an established compatible filler. The extract matrix is moisture and light sensitive and should be protected accordingly, though spermidine survives baking well enough for fortified bakery formats when retention is confirmed by post-process assay.
Cross-Cutting Formulation and Stability Strategy
Across the longevity category, four physicochemical problems recur, and matching the strategy to the active matters more than the format trend.
- Hygroscopic actives such as NMN and nicotinamide riboside hydrolyze and undergo phase transitions in the presence of moisture. Film coating, encapsulation, co-processing with high glass-transition excipients, crystal engineering, and desiccated foil packaging in humidity-controlled lines are the established mitigations [15].
- Poorly water-soluble actives such as urolithin A, resveratrol, fisetin, and coenzyme Q10 are absorption limited. Particle-size reduction, amorphous solid dispersions, cyclodextrin complexation, phospholipid complexes, self-emulsifying systems, and lipid nanoparticles are the core toolkit [16].
- Oxidation-sensitive actives benefit from antioxidants, inert headspace, opaque oxygen-barrier packaging, and microencapsulation.
- Format risk is real: gummies are high-water-activity, often low-pH matrices that accelerate hydrolysis and commonly require 20% to 50% overages, and effervescents are extremely moisture sensitive, making both a poor native fit for NAD+ precursors.
Controlled-release and enteric strategies can help short-half-life actives, but they should be tested case by case. Nicotinamide riboside, for example, is more stable at gastric pH and degrades faster at intestinal pH, so naive intestinal targeting can worsen, not improve, its stability [17].
Regulatory Status: A Moving Target
Regulatory status is the single largest source of formulation risk in this category, and it varies by ingredient and region. NMN’s US position was contested between 2022 and 2025, when the Food and Drug Administration (FDA) initially excluded it from the dietary-supplement definition because of a prior drug investigation, then reversed that position in September 2025 to treat NMN as a lawful dietary ingredient, with follow-up notifications in December 2025 [20]. Each marketer still needs its own new dietary ingredient (NDI) notification, so the status is best described as lawful but procedurally fragile. Synthetic urolithin A is generally recognized as safe (GRAS) in the United States for defined food uses up to 500 mg per serving, supported by a 90-day animal safety assessment [7,8], while spermidine-rich wheat-germ extract relies on self-affirmed GRAS after FDA ceased to evaluate its notification at the notifier’s request [13]. In the European Union, the picture inverts: spermidine-rich wheat-germ extract is an authorized novel food, with adult intake capped at 6 mg/day of spermidine in the EU Union list [12], whereas NMN and urolithin A authorizations remained pending as of mid-2026. Nicotinamide riboside chloride, by contrast, holds an FDA-acknowledged GRAS notice and is authorized as a novel food in the European Union, giving it the cleanest cross-region position among NAD+ precursors [14]. Product developers should confirm the current position against the primary regulator before launch, and against general US regulatory frameworks for labeling and manufacturing.
Quality, Standardization, and the Label-Claim Problem
Quality control is a documented weak point in the longevity category, which makes supplier qualification a formulation-critical step. Identity and assay are established by validated high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS), and for spermidine the polyamine is usually quantified after pre-column derivatization because it lacks a strong native chromophore. The reason this matters is empirical: independent testing of 18 NMN and 5 urolithin A products found NMN content ranging from undetectable (0% of the label claim) to 111.2% of claim, with NMN undetectable in three of the eighteen products tested [19]. Because these actives also degrade on the shelf, specifications should address end-of-shelf-life potency, not only release potency. Practical buyer controls include an ISO 17025-accredited certificate of analysis, identity by HPLC or LC-MS, a stability-indicating method that tracks the relevant degradant such as nicotinamide for NMN, and contaminant panels appropriate to the source, including mycotoxins, heavy metals, and allergen labeling for cereal-derived extracts.
Emerging Trends in Longevity Formulation
The category is consolidating around clinical-grade branded actives that carry their own randomized trials, which gives formulators a documented evidence base but ties efficacy data to a specific manufactured form rather than to the generic molecule. Examples named factually rather than as endorsements include Uthever NMN, Mitopure urolithin A, and spermidineLIFE wheat-germ spermidine, each of which underpins published human studies or a regulatory dossier. Three further trends are shaping decisions. First, regulatory pathway design is now a competitive variable, since the European Novel Food bottleneck, the lag between a safety opinion and market authorization, can delay an ingredient by years while a competitor with an authorized form launches. Second, mechanism-led positioning around autophagy, mitophagy, and NAD+ repletion is replacing vague anti-aging language, which aligns marketing with substantiable structure/function claims. Third, metabotype-driven personalization is emerging, with urolithin A as the clearest case, since non-producers gain the most from direct supplementation. Combination stacks, quercetin and fisetin senolytic formats, and AI-assisted formulation are extending the toolkit, though every bioavailability claim should be backed by pharmacokinetic data.
Hero Ingredient Comparison
Table 1. Formulation-relevant comparison of the three hero longevity ingredients. Doses reflect human studies, not recommendations.
| Ingredient | Mechanism studied | Studied dose | Key formulation challenge | US status (mid-2026) | EU status (mid-2026) |
|---|---|---|---|---|---|
| NMN | NAD+ repletion | 250 to 900 mg/day | Hygroscopicity, hydrolysis to nicotinamide | Lawful after 2025 reversal, NDI required | Not yet authorized (pending) |
| Urolithin A | Mitophagy | 500 to 1000 mg/day | Poor solubility, bioavailability | GRAS for defined food uses | Not yet authorized (pending) |
| Spermidine | Autophagy | 1 to 6 mg/day | Low-dose standardization, moisture | Self-affirmed GRAS / NDI route | Authorized novel food, 6 mg/day cap |
Physicochemical and Stability Specifications
Table 2. Identity and stability properties relevant to handling and packaging.
| Property | NMN | Urolithin A | Spermidine |
|---|---|---|---|
| CAS number | 1094-61-7 | 1143-70-0 | 124-20-9 |
| Molecular weight (g/mol) | 334.22 | 228.20 | 145.25 |
| Water solubility | Freely soluble | Practically insoluble | Delivered in extract |
| Primary instability | Hydrolysis, moisture uptake | Low solubility, conjugation | Matrix moisture, oxidation |
| Lead handling control | Crystalline form, desiccation | Particle-size control | Standardization assay, dry packaging |
Frequently Asked Questions
Why is NMN so difficult to formulate? NMN is very hygroscopic and hydrolyzes to nicotinamide, particularly under heat, moisture, or extreme pH. Stability is improved by selecting a defined crystalline form, keeping water activity low during manufacturing, using desiccants and foil or induction-sealed packaging, and avoiding aqueous, high-heat, and gummy processes that expose the molecule to moisture and temperature.
Are gummies a good format for longevity actives? Gummies are generally a poor native fit for hygroscopic, hydrolysis-prone actives such as NMN. Their high water activity and frequently low pH accelerate degradation, which is why manufacturers often apply 20% to 50% overages and microencapsulation. Capsules and desiccated stick-packs are usually more stable choices for these ingredients.
How is urolithin A bioavailability improved? Urolithin A is poorly water soluble, so bioavailability is improved mainly by particle-size reduction, with micronized grades below a D90 of 50 micrometers absorbed better than coarse material. Lipid-based and dispersible-powder delivery also help, and efficacy data are tied to the specific engineered form used in trials.
Why is spermidine sold as a wheat-germ extract rather than a pure compound? Free-base spermidine is hygroscopic, alkaline, and corrosive, which makes it hard to handle, and the standardized wheat-germ extract has an established European novel-food authorization. Products are therefore dosed by declared spermidine content, so the standardization assay and content uniformity are critical to label accuracy.
Is NMN legal to sell? As of mid-2026, NMN is treated as a lawful dietary ingredient in the United States following an FDA reversal in 2025, though each marketer still needs its own new dietary ingredient notification. It is permitted in Japan and listed in Australia, while in the European Union it had not yet received Novel Food authorization. Status should be confirmed against the current regulator before launch.
What quality checks should buyers require? Buyers should require an ISO 17025-accredited certificate of analysis, identity and assay by validated HPLC or LC-MS, a stability-indicating method tracking the relevant degradant, and contaminant panels suited to the source. Independent testing has shown wide deviations from label claims in this category, so supplier qualification and end-of-shelf-life specifications are essential.
Key Takeaways
Formulation and chemical stability, not efficacy messaging, are the deciding factors for NMN, urolithin A, and spermidine products.
NMN is hygroscopic and hydrolyzes to nicotinamide, so a defined crystalline form, low water activity, and desiccated packaging are essential, and gummy formats are higher risk.
Urolithin A is poorly soluble, and particle-size reduction below a D90 of 50 micrometers is the best-documented bioavailability lever.
Spermidine is dosed in milligram amounts within a standardized wheat-germ extract, so the standardization assay and excipient compatibility govern quality.
Regulatory status differs by ingredient and region and changes over time, so it should be verified against the primary regulator before any launch.
Independent testing has found wide deviations from label claims, making ISO 17025 certificates and stability-indicating methods a formulation-critical control.
Sources
- Yoshino M, Baur JA, Imai SI, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/(accessed 2026-06-23). - Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, dose-dependent trial. GeroScience, 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/(accessed 2026-06-23). - Chen F, Zhou D, Kong APS, et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials. Current Diabetes Reports, 2024.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557618/(accessed 2026-06-23). - Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 2019.
https://pubmed.ncbi.nlm.nih.gov/32694802/(accessed 2026-06-23). - Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9133463/(accessed 2026-06-23). - Liu S, D’Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Network Open, 2022.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788244(accessed 2026-06-23). - Heilman J, Andreux P, Tran N, et al. Safety assessment of urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant-derived ellagitannins and ellagic acid. Food and Chemical Toxicology, 2017.
https://www.sciencedirect.com/science/article/abs/pii/S0278691517304325(accessed 2026-06-23). - US Food and Drug Administration. GRAS Notice No. GRN 791, urolithin A, agency response letter. 2018.
https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=791(accessed 2026-06-23). - Schwarz C, Wirth M, Floel A, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge): a randomized clinical trial. JAMA Network Open, 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9136623/(accessed 2026-06-23). - Kiechl S, Pechlaner R, Willeit P, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. American Journal of Clinical Nutrition, 2018.
https://ajcn.nutrition.org/article/S0002-9165(22)02930-6/fulltext(accessed 2026-06-23). - Eisenberg T, Abdellatif M, Madeo F, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nature Medicine, 2016.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5806691/(accessed 2026-06-23). - European Commission. Commission Implementing Regulation (EU) 2020/443 amending the specification of spermidine-rich wheat germ extract as a novel food. 2020.
https://eur-lex.europa.eu/eli/reg_impl/2020/443/oj/eng(accessed 2026-06-23). - US Food and Drug Administration. GRAS Notice Inventory, GRN 889, spermidine-rich wheat germ extract (evaluation ceased at notifier’s request). 2020.
https://hfpappexternal.fda.gov/Scripts/Fdcc/index.cfm?set=GRASNotices&id=889(accessed 2026-06-23). - US Food and Drug Administration. Agency response letter, GRAS Notice No. GRN 000635, nicotinamide riboside chloride. 2016.
https://www.fda.gov/food/gras-notice-inventory/agency-response-letter-gras-notice-no-grn-000635(accessed 2026-06-23). - Ng LH, Ling JKU, Hadinoto K. Formulation strategies to improve the stability and handling of oral solid dosage forms of highly hygroscopic pharmaceuticals and nutraceuticals. Pharmaceutics, 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9611293/(accessed 2026-06-23). - Bhalani DV, Nutan B, Kumar A, et al. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines, 2022.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495787/(accessed 2026-06-23). - Campbell MTD, Jones DS, Andrews GP, Li S. Understanding the physicochemical properties and degradation kinetics of nicotinamide riboside, a promising vitamin B3 nutritional supplement. Food and Nutrition Research, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6878970/(accessed 2026-06-23). - Degradation kinetics of beta-nicotinamide mononucleotide based on a reliable HPLC quantitative method. 2024.
https://pubmed.ncbi.nlm.nih.gov/38212023/(accessed 2026-06-23). - Sandalova E, Kennedy BK, Maier AB, et al. Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim. GeroScience, 2024.
https://link.springer.com/article/10.1007/s11357-024-01257-2(accessed 2026-06-23). - NutraIngredients. FDA declares NMN lawful in dietary supplements (and related 2025-2026 regulatory coverage). William Reed, 2025.
https://www.nutraingredients.com/Article/2025/09/30/fda-declares-nmn-lawful-in-dietary-supplements/(accessed 2026-06-23).
These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.
Read more on longevity ingredients here:
In Search of Longevity:
Effective and Stable Senomorphic Apigenin Delivery System
